MRC1 and glioblastoma: The classification was further refined by separating the rare glioblastoma cases with MMR deficiency into a G3/MMR molecular subgroup, a spin-off of the G3/NF1 subgroup, since RAS activation appears to be dominant in the MMR tumors, as well.